Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

2.

Computationally-driven identification of antibody epitopes.

Hua CK, Gacerez AT, Sentman CL, Ackerman ME, Choi Y, Bailey-Kellogg C.

Elife. 2017 Dec 4;6. pii: e29023. doi: 10.7554/eLife.29023.

3.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2017 Oct 3;21(1):222-235. doi: 10.1016/j.celrep.2017.09.024.

4.

Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Molinos-Albert LM, Clotet B, Blanco J, Carrillo J.

Front Immunol. 2017 Sep 19;8:1154. doi: 10.3389/fimmu.2017.01154. eCollection 2017. Review.

5.

Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.

Andrabi R, Su CY, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DR.

Immunity. 2017 Sep 19;47(3):524-537.e3. doi: 10.1016/j.immuni.2017.08.006. Epub 2017 Sep 12. Erratum in: Immunity. 2017 Nov 21;47(5):1004.

PMID:
28916265
6.

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH.

Sci Transl Med. 2017 Sep 6;9(406). pii: eaal1321. doi: 10.1126/scitranslmed.aal1321.

PMID:
28878010
7.

Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.

Moody MA, Pedroza-Pacheco I, Vandergrift NA, Chui C, Lloyd KE, Parks R, Soderberg KA, Ogbe AT, Cohen MS, Liao HX, Gao F, McMichael AJ, Montefiori DC, Verkoczy L, Kelsoe G, Huang J, Shea PR, Connors M, Borrow P, Haynes BF.

Sci Immunol. 2016 Jul 29;1(1):aag0851. doi: 10.1126/sciimmunol.aag0851. Epub 2016 Jul 29.

8.

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.

Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C.

J Virol. 2017 Aug 24;91(18). pii: e00828-17. doi: 10.1128/JVI.00828-17. Print 2017 Sep 15.

9.

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, Eroshkin AM, Guenaga J, Kaushik K, Kulp DW, Liu J, McCoy LE, Oom AL, Ozorowski G, Post KW, Sharma SK, Steichen JM, de Taeye SW, Tokatlian T, Torrents de la Peña A, Butera ST, LaBranche CC, Montefiori DC, Silvestri G, Wilson IA, Irvine DJ, Sanders RW, Schief WR, Ward AB, Wyatt RT, Barouch DH, Crotty S, Burton DR.

Immunity. 2017 Jun 20;46(6):1073-1088.e6. doi: 10.1016/j.immuni.2017.05.007.

10.

Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.

Powell RLR, Totrov M, Itri V, Liu X, Fox A, Zolla-Pazner S.

J Virol. 2017 Aug 10;91(17). pii: e00410-17. doi: 10.1128/JVI.00410-17. Print 2017 Sep 1.

PMID:
28615206
11.

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.

Brandenberg OF, Magnus C, Rusert P, Günthard HF, Regoes RR, Trkola A.

PLoS Pathog. 2017 May 4;13(5):e1006313. doi: 10.1371/journal.ppat.1006313. eCollection 2017 May.

12.

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.

Cheedarla N, Precilla KL, Babu H, Vijayan KKV, Ashokkumar M, Chandrasekaran P, Kailasam N, Sundaramurthi JC, Swaminathan S, Buddolla V, Vaniambadi SK, Ramanathan VD, Hanna LE.

Sci Rep. 2017 Apr 24;7:46557. doi: 10.1038/srep46557.

13.

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF.

Cell Rep. 2017 Feb 28;18(9):2175-2188. doi: 10.1016/j.celrep.2017.02.003.

14.

Identification and specificity of broadly neutralizing antibodies against HIV.

McCoy LE, Burton DR.

Immunol Rev. 2017 Jan;275(1):11-20. doi: 10.1111/imr.12484. Review.

15.

Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.

Kwong PD, Chuang GY, DeKosky BJ, Gindin T, Georgiev IS, Lemmin T, Schramm CA, Sheng Z, Soto C, Yang AS, Mascola JR, Shapiro L.

Immunol Rev. 2017 Jan;275(1):108-128. doi: 10.1111/imr.12480. Review.

16.

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.

Borrow P, Moody MA.

Immunol Rev. 2017 Jan;275(1):62-78. doi: 10.1111/imr.12504. Review.

17.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

18.

Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.

Moore PL, Gorman J, Doria-Rose NA, Morris L.

Immunol Rev. 2017 Jan;275(1):217-229. doi: 10.1111/imr.12501. Review.

19.

Germline-targeting immunogens.

Stamatatos L, Pancera M, McGuire AT.

Immunol Rev. 2017 Jan;275(1):203-216. doi: 10.1111/imr.12483. Review.

20.

Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.

Kepler TB, Wiehe K.

Immunol Rev. 2017 Jan;275(1):129-144. doi: 10.1111/imr.12513. Review.

Supplemental Content

Support Center